Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Price Performance

EVGN opened at $1.41 on Thursday. The business has a fifty day moving average price of $2.05 and a 200 day moving average price of $3.92. The stock has a market capitalization of $7.54 million, a price-to-earnings ratio of -0.31 and a beta of 1.36. Evogene has a 12 month low of $1.35 and a 12 month high of $10.40.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.